A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies

(2012) James J. Driscoll et al.   Anti-Cancer Agents in Medicinal Chemistry

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

(2012) Ravi Vij et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

(2012) M. Alsina et al.   CLINICAL CANCER RESEARCH

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

(2012) Sundar Jagannath et al.   Clinical Lymphoma Myeloma & Leukemia

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

(2011) D. Chen et al.   CURRENT CANCER DRUG TARGETS

Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats

(2011) J. Yang et al.   DRUG METABOLISM AND DISPOSITION

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

(2011) Erika Suzuki et al.   PLoS One

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

(2010) Manish A. Shah et al.   INVESTIGATIONAL NEW DRUGS

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

(2009) Carol Aghajanian et al.   GYNECOLOGIC ONCOLOGY

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

(2009) M. J. Williamson et al.   MOLECULAR CANCER THERAPEUTICS

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

(2008) J. E. Rosenberg et al.   ANNALS OF ONCOLOGY

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE